Construction and validation of a novel IGFBP3-related signature to predict prognosis and therapeutic decision making for Hepatocellular Carcinoma
PeerJ · 2023
DOI: 10.7717/peerj.15554 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Jianlin Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: High-level Hospital Foster Grant of Fujian Provincial Hospital, Medical Vertical Project of Fujian Province, Natural Science Foundation of Fujian Province.
Abstract (Originalsprache)
Background
IGFBP3 plays a pivotal role in carcinogenesis by being anomalously expressed in some malignancies. However, the clinical value of IGFBP3 and the role of IGFBP3-related signature in HCC remain unclear.
Methods
Multiple bioinformatics methods were used to determine the expression and diagnostic values of IGFBP3. The expression level of IGFBP3 was validated by RT-qPCR and IHC. A IGFBP3-related risk score (IGRS) was built via correlation analysis and LASSO Cox regression analysis. Further analyses, including functional enrichment, immune status of risk groups were analyzed, and the role of IGRS in guiding clinical treatment was also evaluated.
Results
IGFBP3 expression was significantly downregulated in HCC. IGFBP3 expression correlated with multiple clinicopathological characteristics and demonstrated a powerful diagnostic capability for HCC. In addition, a novel IGRS signature was developed in TCGA, which exhibited good performance for prognosis prediction and its role was further validated in GSE14520 . In TCGA and GSE14520 , Cox analysis also confirmed that the IGRS could serve as an independent prognostic factor for HCC. Moreover, a nomogram with good accuracy for predicting the survival of HCC was further formulated. Additionally, enrichment analysis showed that the high-IGRS group was enriched in cancer-related pathways and immune-related pathways. Additionally, patients with high IGRS exhibited an immunosuppressive phenotype. Therefore, patients with low IGRS scores may benefit from immunotherapy.
Conclusions
IGFBP3 can act as a new diagnostic factor for HCC. IGRS signature represents a valuable predictive tool in the prognosis prediction and therapeutic decision making for Hepatocellular Carcinoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
- Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, china.
- Central Laboratory, Fujian Provincial Hospital, Fuzhou, China.
- Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, China.
- Integrated Chinese and Western Medicine College, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
- Department of Pathology, Fujian Provincial Hospital, Fuzhou, China.
Förderung
- High-level Hospital Foster Grant of Fujian Provincial Hospital
- Medical Vertical Project of Fujian Province
- Natural Science Foundation of Fujian Province
Zitieren
APA
Chen, J., Zhuang, W., Xia, Y., Yin, X., Tu, M., Zhang, Y., Zhang, L., Huang, H., Zhang, S., You, L., & Huang, Y. (2023). Construction and validation of a novel IGFBP3-related signature to predict prognosis and therapeutic decision making for Hepatocellular Carcinoma. PeerJ. https://doi.org/10.7717/peerj.15554
Vancouver
Chen J, Zhuang W, Xia Y, Yin X, Tu M, Zhang Y, et al. Construction and validation of a novel IGFBP3-related signature to predict prognosis and therapeutic decision making for Hepatocellular Carcinoma. PeerJ. 2023. doi:10.7717/peerj.15554
BibTeX
@article{Chen2023,
author = {Chen, Jianlin and Zhuang, Wanzhen and Xia, Yu and Yin, Xiaoqing and Tu, Mingshu and Zhang, Yi and Zhang, Liangming and Huang, Hengbin and Zhang, Songgao and You, Lisheng and Huang, Yi},
title = {Construction and validation of a novel IGFBP3-related signature to predict prognosis and therapeutic decision making for Hepatocellular Carcinoma},
journal = {PeerJ},
year = {2023},
doi = {10.7717/peerj.15554}
}
EUVIMED